KA 2237

Drug Profile

KA 2237

Alternative Names: KA2237

Latest Information Update: 01 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karus Therapeutics
  • Developer Karus Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma
  • Preclinical Inflammation

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from in vitro and in vivo studies in Mantle cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Jul 2016 Phase-I clinical trials in B-cell lymphoma in USA (PO) (NCT02679196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top